Scholarlink

Background <p>Despite advances in multimodal therapy, high-risk neuroblastoma (HR-NB) continues to have poor outcomes. Response to induction chemotherapy is a key predictor of long-term survival, yet intensive multi-agent regimens have not substantially improved prognosis.</p> Objectives <p>This study aims to evaluate the efficacy and safety of adding bevacizumab to conventional induction chemotherapy in HR-NB.</p> Methods <p>This prospective, multicenter, randomized controlled trial will enroll newly diagnosed high-risk neuroblastoma patients, randomized to receive either conventional induction chemotherapy alone (control) or bevacizumab plus conventional induction chemotherapy (intervention). Response to induction therapy will be assessed according to standard criteria, and patients achieving a complete or good partial response will proceed to autologous stem cell transplantation (ASCT). All participants will be followed for at least 2&#xa0;years to evaluate event-free survival (EFS) and overall survival (OS). The primary outcome, response rate, will be reported as a proportion, and EFS and OS will be analyzed using Kaplan–Meier plots and log-rank tests. The secondary outcomes (toxicity and minimal residual disease) will be reported as proportions. Prognostic factors will be evaluated with univariate and multivariate Cox regression analyses.</p> Expected outcomes <p>The study aims to demonstrate that adding bevacizumab to conventional induction chemotherapy improves response rates, increases the proportion of patients eligible for autologous stem cell transplantation (ASCT), and improves survival outcomes, with manageable toxicities.</p> Trial registration <p>This study is registered with the Clinical Trials Registry of India (CTRI/2024/09/074065, dated: 19/09/2024).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月21日

查看全文
  • Jagdish Prasad Meena,
  • Debasish Sahoo,
  • Harshita Makkar,
  • Sujata Bhattacharya,
  • Aditya Kumar Gupta,
  • Deepam Pushpam,
  • Manisha Jana,
  • Aanchal Kakkar,
  • Bangkim Chandra Khangembam,
  • Maroof Ahmad Khan,
  • Narendra Kumar Chaudhary,
  • Nidhi Chopra,
  • Prashant Prabhakar,
  • Amitabh Singh,
  • Shilpa Khanna Arora,
  • Nishant Verma,
  • Sonali Mohapatra,
  • Maharshi Trivedi,
  • Parichay Singh,
  • Vineeta Gupta,
  • Pankaj Dwivedi,
  • Sameer Bakhshi,
  • Imteyaz Ahmad Khan,
  • Lata Singh,
  • Piali Mandal,
  • Rachna Seth

摘要

Background

Despite advances in multimodal therapy, high-risk neuroblastoma (HR-NB) continues to have poor outcomes. Response to induction chemotherapy is a key predictor of long-term survival, yet intensive multi-agent regimens have not substantially improved prognosis.

Objectives

This study aims to evaluate the efficacy and safety of adding bevacizumab to conventional induction chemotherapy in HR-NB.

Methods

This prospective, multicenter, randomized controlled trial will enroll newly diagnosed high-risk neuroblastoma patients, randomized to receive either conventional induction chemotherapy alone (control) or bevacizumab plus conventional induction chemotherapy (intervention). Response to induction therapy will be assessed according to standard criteria, and patients achieving a complete or good partial response will proceed to autologous stem cell transplantation (ASCT). All participants will be followed for at least 2 years to evaluate event-free survival (EFS) and overall survival (OS). The primary outcome, response rate, will be reported as a proportion, and EFS and OS will be analyzed using Kaplan–Meier plots and log-rank tests. The secondary outcomes (toxicity and minimal residual disease) will be reported as proportions. Prognostic factors will be evaluated with univariate and multivariate Cox regression analyses.

Expected outcomes

The study aims to demonstrate that adding bevacizumab to conventional induction chemotherapy improves response rates, increases the proportion of patients eligible for autologous stem cell transplantation (ASCT), and improves survival outcomes, with manageable toxicities.

Trial registration

This study is registered with the Clinical Trials Registry of India (CTRI/2024/09/074065, dated: 19/09/2024).